Cutting-edge artificial intelligence platform to analyze antipsychotic drug use data from leading brain development institute to predict patient outcomes. WASHINGTON DC, and BALTIMORE, MD – Feb. 15th, 2018 ― BullFrog…
Continue Reading
For media inquiries, please contact:
Recent Articles
- BullFrog AI Signs Memorandum of Understanding with KBP Biosciences
- BullFrog AI Announces New Chief Technology Officer
- BullFrog AI Announces Strategic Partnership with The Lieber Institute for Brain Development to Improve Antipsychotic Drug Selection
- Johns Hopkins Applied Physics Laboratory Licenses Big-Data Analysis Tool to BullFrog AI
- BULLFROG AI LAUNCHES